rebaudioside A/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on fasting blood glucose
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Changes from baseline for rebaudioside A and placebo, respectively, in fasting glucose (7.5+/-3.7mg/dL and 11.2+/-4.5mg/dL), insulin (1.0+/-0.64microU/mL and 3.3+/-1.5microU/mL), and C-peptide (0.13+/-0.09ng/mL and 0.42+/-0.14ng/mL) did not differ significantly (p>0.05 for all).”
Quoted verbatim from Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus.. - Study
- RCT
- Duration
- 4 months
- Dose
- 1000 mg rebaudioside A for 16 weeks
- Population
- men and women aged 33-75 years with type 2 diabetes mellitus
Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus.2008PMID:18555575Permalink
Keep reading
- Everything the graph holds on rebaudioside A
- Every compound studied against Fasting blood glucose
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PFDGYWZ6G0KFDB5GTNXGBP